

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

**UPDATE ON THE QUALIFICATION OF JOINT COMPANY
SECRETARY AND RESIGNATION OF JOINT COMPANY SECRETARY
AND
CHANGE OF PROCESS AGENT**

References are made to the prospectus of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”) dated September 13, 2023 in relation to, among other things, the appointment of Mr. Zheng Jianhua (“**Mr. Zheng**”) and Ms. Lai Janette Tin Yun (“**Ms. Lai**”) as the joint company secretaries of the Company (each a “**Joint Company Secretary**”) and the waiver (the “**Waiver**”) granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) for three years up to September 24, 2026.

**UPDATE ON THE QUALIFICATION OF JOINT COMPANY SECRETARY AND
RESIGNATION OF JOINT COMPANY SECRETARY**

The board of directors (the “**Board**”) of the Company is pleased to announce that on September 18, 2026, the Stock Exchange confirmed that Mr. Zheng, a current Joint Company Secretary, is qualified to act as the company secretary of the Company under Rules 3.28 and 8.17 of the Listing Rules upon expiry of the Waiver on September 24, 2026. Accordingly, Ms. Lai will resign as a Joint Company Secretary with effect from September 30, 2026. Mr. Zheng will continue to serve as the sole company secretary of the Company following the resignation of Ms. Lai.

Ms. Lai has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Company would like to express its gratitude to Ms. Lai for her valuable contribution to the Company during her term of office.

CHANGE OF PROCESS AGENT

The Board further announces that (i) Ms. Lai has resigned as the authorised representative of the Company (the “**Process Agent**”) for accepting service of process and notices on behalf of the Company in Hong Kong as required under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) with effect from September 30, 2026, and (ii) Ms. Mak Sin Ki has been appointed as the Process Agent with effect from September 30, 2026.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, September 30, 2026

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.